Netflix's new horror TV series, "The Haunting of Hill House," has quickly grown in popularity to become one of Netflix's best-reviewed shows. But one episode stands out for its immersive long takes.

Episode six features a series of one-shot takes, the longest being 17 minutes, as it flashes between the past and the present. A new Netflix featurette goes behind the scenes of the episode with the cast and crew.

When writing the script, the writer and director Mike Flanagan said that he "realized that a lot of the camera choreography needed to be incorporated into the draft itself, because we were doing 18-page scenes without any cuts."

Flanagan said he "wanted an episode that would appear to take place essentially in real time, in one single shot."

"It turned into a challenge unlike anything else I've ever had in a production," he continued. "The set had to actually be constructed with this episode in mind — we knew that we had certain shots that were going to require us to walk through the house in its entirety."

Carla Gugino, who plays Olivia Crain, the troubled mother on the show, added that "everyone has to be absolutely in sync with each other, and if one thing is off, the take is gone."

Watch the full video:

Uber may be delivering burgers by drones as soon as 2021.

According to a job listing spotted by The Wall Street Journal, Uber is looking to hire an operations executive to make drone delivery functional by next year and available for commercial use by 2021.

The job post referenced UberExpress — which is the internal name for UberEats' drone delivery initiative — and said the executive would help "enable safe, legal, efficient and scalable flight operations" for the program.

The job listing has since been taken down from Uber's site after a spokesperson told The Wall Street Journal that it "does not fully reflect our program, which is still in very early days."

In May, Uber CEO Dara Khosrowshahi referenced the drone project at the company's Uber Elevate conference — which was dedicated to flying cars. "It's my personal belief that a key to solving urban mobility is flying burgers in any city," he said. "We need flying burgers. Everyone needs it, so we're working on that."

Khosrowshahi thinks drones could significantly cut down delivery time from today's UberEats couriers. Five to thirty-minute delivery time is the goal, he said at the conference.

Uber's foray into drone delivery is another service it's looking to add ahead of its expected 2019 IPO to ward off naysayers who worry about its past scandals and potential profitability from its core ride-hailing business, according to The Wall Street Journal.

Drone delivery is no easy task, however, as industry giants like Amazon have learned. Amazon announced in 2013 that it planned to roll out its drone delivery program within four to five years, but it suffered a setback this year when the company was not included in the U.S. Transportation Department drone-operations pilot program.

Uber was accepted into the Transportation Department's pilot in San Diego, which will focus on border protection and food delivery.

A rendering of Lime’s new office it’s building in San Francisco. The design could hint at what Lime wants to do with its retail store branding.

I was really tired this weekend (from the week) and didn’t feel like doing anything other than laying on the couch near Amy and reading. She was also tired, as she spent the week in Wellesley at a board meeting and a bunch of other Wellesley related stuff, so even though the Boulder weather was magnificent, we stayed home other than a quick trip to Boulder to get our eyes checked and have sushi with some friends. Oh, and took really long naps both afternoons.

By Sunday night I was tired of reading (but Amy wasn’t) so I went downstairs and watched Finding Traction, the documentary about Nikki Kimball’s monstrous performance on the 273 mile Long Trail in Vermont. While I’m limited to running marathons, I find inspiration from watching ultras …

The book list started with me finishing a book I’d started earlier in the week. I read mostly on the Kindle this weekend, but John Doerr’s book came in the mail in physical form so I read it that way.

Mastering the Market Cycle: Getting the Odds on Your Side: Howard Marks (Oaktree) is a brilliant investor (and great writer) so I read everything by him I can get my hands on (and there’s a lot of it going back to 1990.) Not surprisingly, I learned a few key things from this book and it reinforced a bunch of others I already knew.

Power to the Startup People: How To Grow Your Startup Career When You’re Not The Founder: There is an infinite number of books now aimed at startup founders and entrepreneurs, but very few aimed at startup employees. Sarah Brown is a Boulder friend (now living in SF) and this is a really good book. There are lots of Boulder stories and people in it, but Sarah does a great job of covering a lot of ground that is generally useful to anyone considering working in, or already working in a startup. It’s the second “startup employee” book that I think is really good, following Jeff Bussgang’s Entering StartUpLand: An Essential Guide to Finding the Right Job (which is referenced a few times in Sarah’s book.)

Year of Yes: How to Dance It Out, Stand In the Sun and Be Your Own Person: In my effort to read more memoirs by women, I enjoyed Shonda Rimes book. I can’t remember who referred it to me, but it was good and added a dimension to my memoir reading that had a lot more X and no Y in it. Amy and I regularly watched both Grey’s Anatomy (at least the first four seasons) and Scandal (again – maybe four seasons) so Shonda Rimes has entertained us a lot. With this book, she helped widen my perspective on a number of things I hadn’t thought much about.

From Like to Love: Inspiring Emotional Commitment from Employees and Customers: Keith Alper is a long-time friend – we were both on the YEO board in the mid-1990s, spent a lot of time with the Kauffman Foundation when Jana Matthews was there, and have continued to connect on numerous things over the years. This book embodies everything I’d expect from Keith, is a good read and had some fun new suggestions in it. Definitely worth reading if you are a CEO and you like the word “love” in a business context. And, if the word “love” in a business context scares you, then this book is also for you.

Measure What Matters: OKRs: The Simple Idea that Drives 10x Growth: John Doerr is well-known as a long-time advocate of OKRs. Today, I hear the word OKR in a lot of contexts where I’m 100% certain the company is implementing them incorrectly. If you are using OKRs, please read this book. And, if you are thinking about OKRs, please read this book.

Ready for Monday? I’m going to start things off with a short run.

Also published on Medium.

The US healthcare industry as it exists today is not sustainable. An aging patient population and rising burden of chronic disease have caused healthcare costs to skyrocket and left providers struggling to keep up with demand for care.

Business Insider Intelligence

Meanwhile, digital technologies in nearly every consumer experience outside of healthcare have raised patients' expectations for good service to be higher than ever.

One of the key mechanisms through which healthcare providers can finally evolve their outdated practices and exceed these expectations is wearable technology.

Presently, 33% of US consumers have adopted wearables, such as smartwatches and fitness trackers, to play a more active role in managing their health. In turn, insurers, providers, and employers are poised to become just as active leveraging these devices - and the data they capture - to abandon the traditional reimbursement model and improve patient outcomes with personalized, value-based care.

Adoption is going to keep climbing, as more than 80% of consumers are willing to wear tech that measures health data, according to Accenture — though they have reservations about who exactly should access it.

A new report from Business Insider Intelligence, Business Insider's premium research service, follows the growing adoption of wearables and breadth of functions they offer to outline how healthcare organizations and stakeholders can overcome this challenge and add greater value with wearable technology.

For insurers, providers, and employers, wearables present three distinct opportunities:

Want to Learn More?

The Wearables in US Healthcare Report details the current and future market landscape of wearables in the US healthcare sector. It explores the key drivers behind wearable usage by insurers, healthcare providers, and employers, and the opportunities wearables afford to each of these stakeholders.

By outlining a successful case study from each stakeholder, the report highlights best practices in implementing wearables to reduce healthcare claims, improve patient outcomes, and drive insurance cost savings, as well as how the evolution of the market will create new, untapped opportunities for businesses.

A startup that wants to reinvent the way we take care of seniors in America just raised hundreds of millions as it gears up to launch its new plans in 2019.

Devoted Health on Tuesday said that it had raised $300 million in a series B round led by Andreessen Horowitz, bringing its total funding to $369 million in funding. The company is based in Waltham, Massachusetts, but it'll initially offer Medicare Advantage plans in parts of Florida, starting next year. Devoted is the latest firm to enter Medicare Advantage, the private side of the government-funded Medicare program for seniors. It'll have to compete for customers immediately with big, entrenched rivals like Humana, UnitedHealth Group and soon-to-be-merged CVS Health and Aetna. UnitedHealth on Tuesday said that it covers 4.9 million Medicare Advantage members, 12 percent more than a year earlier. About 19 million people were covered by Medicare Advantage last year.

Oscar Health, known for its individual plans on the Affordable Care Act insurance exchanges, said in August that it plans to move into the Medicare Advantage market after raising $375 million from Alphabet. Clover Health, which was founded in 2014, has been offering insurance plans in four states, with plans to expand into three more in 2019 Devoted was founded in 2017 by brothers Ed and Todd Park. Prior to Devoted, Todd co-founded health IT company Athenahealth and served as chief technology officer of the US during the Obama administration. Ed, who serves as Devoted's CEO, was formerly chief technology officer and later chief operating officer at Athenahealth.The company's plans might look a bit different from traditional insurance in that Devoted plans to do more than pay for visits to doctors and hospitals. It's also hiring nurses and other employees aimed at keeping seniors healthier and out of the hospital.

Because health insurers are in charge of paying for healthcare, the companies tend to know what's going on with a particular patient: have they been in for a check-up, or have they had a recent trip to the emergency room? Knowing that, the insurer — in this case Devoted — can clue in the other parts of the system so that the primary care doctor knows when his or her patient has been in the hospital and can follow up with them, for example.

To do that however, the Devoted team had to build out its own technology to process claims as well as build out its networks of doctors that it can work with. The latest funding round is being used to build out the technology to help them do that.

"Now we can sprint," DJ Patil, Devoted's head of technology told Business Insider.

Medicare Advantage, the private version of the government health insurance program for the elderly and some disabled people, has been steadily growing. As of 2017, 33% of people on Medicare were in one of these plans. Individuals can typically choose to enroll in either Traditional Medicare or Medicare Advantage plans. Medicare Advantage works like private insurance does for those under 65. It's designed to allow people to shop around and choose among different plans, which may restrict which doctors and hospitals individuals can use. The US government in turn pays the insurers a certain amount for each person who is covered, creating an incentive for the insurer to try to keep that person healthy and out of the hospital. If the insurer does a good job of caring for its customer at a low cost, it can keep the extra funds as profits.

"Medicare Advantage is today the simplest way to align financial incentives across the various parties in the system," Venrock partner Bryan Roberts, who's an investor and board member at Devoted told Business Insider. "Therefore, you can drive better efficiency in the healthcare system."

Vijay Pande, a partner at Andreessen Horowitz, said a key reason his firm led Devoted's fundraising was because of the implications plans like Devoted's could have beyond Florida, and even beyond just Americans 65 and older.

"The future could look like Medicare Advantage for all," Pande said.

See also:

"Being able to put yourself in someone else's shoes is really important."

This is true of life in general, but it's especially true when you're asking your boss for a raise.

According to Libby Leffler, who is the vice president of membership at personal finance company SoFi as well as a former Googler and Facebook executive, the first thing to do when you're planning to petition your manager for a salary bump is to "consider where you're coming from and where they're coming from."

For example: Are they trying to manage an already-tight budget for the division? Are they under strict orders only to grant raises for knock-it-out-of-the-park performance? Once you understand their goals and constraints, you can adjust your pitch accordingly.

Leffler's advice recalls insights from Daniel Shapiro, founder and director of the Harvard International Negotiation Program, and author of "Negotiating the Nonnegotiable." Shapiro previously told Business Insider that it can be helpful to play the role of your boss while a friend or colleague plays you.

The idea is to think and feel how your boss might be thinking and feeling — and to then tailor your strategy so it really resonates with them.

Remember, too, Leffler said: You can negotiate for outcomes other than financial ones. "Compensation is whatever these things mean to you," Leffler said. It can be flexible hours, extra vacation time, equity, or bonus pay. Figure out what exactly you want (and what your boss might be most likely to concede).

Leffler's most important piece of wisdom? "Practice, practice, practice your pitch before walking in." She'd never advocate going in cold.

Leffler said, "You want to take all these steps in advance to really set yourself up for success."

Anne Wojcicki, the CEO and founder of popular Silicon Valley gene testing company 23andMe, doesn't feel like the company is currently offering what she called a "complete product."

That's because the current gene testing kit — which includes health screenings for some of the genes involved in Alzheimer's, Parkinson's, and breast cancer — does not include a test that looks at how you process medications including those for depression.

Those DNA tests, which assess genes involved in the break down of antidepressants in the body, are currently being offered by psychiatrists and Albertsons pharmacists in three major cities at a hefty price tag of $750. Just last month, another Silicon Valley genetics testing startup called Color Genomics began offering the test as part of its $250 kits.

And on Tuesday at a conference organized by Rock Health, one of Silicon Valley's premier health-tech funding groups, Wojcicki said she hoped her company could include that kind of test in its product lineup soon.

But many scientists feel the tests don't offer a clear benefit to people and in some cases are not worth the money. Among other issues, the tests may give conflicting results to the same patient for the same medication and don't tell providers which specific medication is best, according to experts.

Lydia Ramsey/Business Insider In the early days of 23andMe, the company included a test for depression medications in its lineup of health offerings, Wojcicki said. But in 2013, the Food and Drug Administration forced the company to stop selling those products and get federal approval on the grounds that the tests could be misinterpreted as health advice. The company was allowed to continue selling the genealogy component of its kit, which looks at ancestry.

Last year, the FDA gave the company the green light to again sell some of its health screenings. On the heels of that decision, 23andMe rolled out a limited selection of some of its original products. The most recent addition, unveiled in March, is a test for some of the genes involved in the risk of developing breast cancer, also known as BRCA genes.

Now, the company is only missing one of those original health products, Wojcicki said: a test for depression medications, also called pharmacogenomics.

"The only one we don't have back yet is pharmacogenomics. We used to have that and we'd like to have that one come back," Wojcicki said on Tuesday at a panel discussion at the Rock Health Summit in San Francisco.

"When we can bring pharmacogenomics back, then we have a complete product back," she said.

It remains to be seen how the company would roll out such a test. Because 23andMe sells its tests directly to people (they can be purchased online and at a selection of drug stores), it would need to get FDA approval before selling an additional health product. The test could be incorporated into the existing health lineup, which currently includes tests for Alzheimer's, Parkinson's, and breast cancer for $199, or it could be sold as a stand-alone test.

Color Genomics chose to incorporate its new pharmacogenomics product into its existing $250 test. Unlike 23andMe, which sells its services directly to consumers, Color requires people to order their tests through a medical provider. In addition, the company mandates talking with a professional genetics counselor and a clinical pharmacist to avoid potentially dangerous misinterpretations of the results.

Genomind and Assurex, the two companies who offer a standalone pharmacogenomics product, sell the test through psychiatrists and some pharmacists for $750.

Wojcicki did not provide further details on how much the test — should the company ultimately choose to offer it — would cost or when it would be available. A company representative also declined to offer Business Insider more information about the test. But Wojcicki said she saw the pharmacogenomics service as part of the company's overall mission to help empower customers with more data about themselves and prevent negative health outcomes when possible.

"I think one thing genetics can do is help prevent a lot of early deaths," Wojcicki said.

Former position at Google: Software developer

Why he left: Breisacher was one of about a dozen Googlers who left the company in April to protest Google's controversial collaboration in which it provides the US Department of Defense with artificial-intelligence technology.

After thousands of employees signed a petition, Google announced it would cease work on the project next year.

"This is obviously a big deal, and it's very encouraging, but this only happened after months and months of people signing petitions and [internal debate] and people quitting," Breisacher told Business Insider.

Breisacher said his decision to leave was also influenced by Google's sponsorship of a conservative political conference and its failure to act decisively after YouTube videos related to LGBT issues were flagged as inappropriate on the site.

"When I started, Google had a reputation as a pro-gay, pro-trans company," Breisacher, who is gay, told Business Insider. "I guess I'm disillusioned. I know that Google is a for-profit company and you shouldn't expect it to do things purely for the good of the world. But in the past, we would expect leaders to listen to the employees and to think carefully about issues and not to cross certain lines.

"Things have changed at Google."

Health-related investment data for 2015-18 compiled from Pitchbook, Crunchbase, and SEC Edgar

Chinese VCs are investing in a wide range of innovative life science and biotech startups. (Photo by Eugeneonline via Getty Images)

Despite heavy investment by China’s leading VCs, Silicon Valley is doubling down in the US health sector.  (AFP PHOTO / POOL / JASON LEE)

Krishna Yeshwant (GV) at TechCrunch Disrupt NY 2017

Deficiencies in China’s health sector has historically led to troublesome outcomes.  Now the government is jump-starting investment through supportive policy. (Photo by Alexander Tessmer / EyeEm via Getty Images)

Google is making fundamental changes to the way Android works inside Europe, thanks to a $5 billion fine imposed by the European Union earlier this year.

Here's a summary of the changes, because it's complicated:

Until these changes actually come into effect, it is hard to know precisely what the outcome for consumers will be, but here's a walkthrough of a few possible scenarios.

Android phones become more expensive inside Europe

The Samsung Note 9. Hollis Johnson/Business Insider

When the EU first hit Google with a fine, legal experts last year warned that Android phones might become pricier as a result.

To understand why Android phones might become pricier as a result of this fine, it's key to remember that search advertising is Google's primary moneymaker on desktop and mobile. And increasingly, mobile is becoming more important thanks to the fact we're all buried in our smartphones.

Android has remained free because Google, by demanding phone makers preinstall Google Search, has ensured it can keep making big money from search ads on mobile. Thanks to the EU, that near-guaranteed source of revenue is under threat and Google has had to come up with another way to ensure it can make money from Android.

Charging for Android itself doesn't make sense — it's in Google's interests to make the OS as widely available as possible. Cue licensing agreements for its more popular apps.

Phone manufacturers may realise that their customers still want out-of-the-box access to Google services such as Maps and Search, and accordingly cough up for the new licences. And those costs may be passed to consumers, who will suddenly see the price of Android phones rise.

But this is dependent on a few things. One is how many phone makers decide to license Google apps, rather than pre-install rival services. Another is that Google may effectively cancel out licensing payments by paying phone makers to place Search and Chrome prominently on their homescreens. It'll cost Google a little more money, but the guaranteed income from search ads may be worth it.

The Android ecosystem's fragmentation problem gets worse

Google's Pixel 3 is the company's answer to fragmentation frustrations. Hollis Johnson/Business Insider

When you buy an iPhone, you know exactly what you're getting. That's not such a guarantee when you're shopping around for Android phones, thanks to the fact that manufacturers control the timing of operating system updates.

Fragmentation is an ongoing headache for Google. This refers to the fact that lots of different phones run on different versions of Android. This is bad for app developers and for security. Fragmentation is why cool new apps tend to hit the iPhone before they get to Android.

The Developer Alliance, which has been on Google's side throughout its EU ordeal, wrote on Tuesday that the "specter of fragmentation is back." That's thanks to Google deciding to allow non-compatible Android forks as a result of the EU fine.

Android forks are popular, especially with people who crave the freedom to tinker with their phones. Non-compatible Android forks are locked out from Google services, so they're also popular with anti-corporate types. Amazon created an Android fork, FireOS, to run on its Fire Tablets and other hardware, but Google essentially froze that system out of smartphones. Unfortunately, forks also mean Android doesn't exactly look like a consistent experience.

According to the alliance: "There is a risk that diverging versions of Android will lead to devices where apps cost more to develop and may not work for all users. Google's efforts to limit fragmentation have led to a better platform for users, developers, and phone makers. The Developers Alliance hopes that clear labelling helps to reduce the potential for user confusion between compatible and incompatible Android devices."

Facebook's bad year seems to keep getting worse.

Brian Wieser doesn't expect it to improve anytime soon, and thinks that's a good reason to sell the company's stock.

"We continue to see these issues as representative of systemic problems impacting the company," Wieser, a financial analyst who covers Facebook for Pivotal Research Group, said in a research note on Wednesday. He continued: "We're not doubting they [can] be fixed, but the fact that problems keep emerging reinforces our view that the company is not as in control of its business as it needs to be."

Facebook has been pummeled by a seemingly endless string of fiascos, scandals, and public-relations nightmares this year. Just on Wednesday, the Wall Street Journal reported that Facebook has been spotty about taking down pages from fake veterans groups, while USA Today reported that Facebook was removing ads that mentioned African-Americans and other minority groups, citing them as "political," when the ads weren't actually promoting political causes or candidates.

Meanwhile, in the last week, Facebook acknowledged that a security breach was worse than it had disclosed before, at least in terms of the data that was compromised, noted Wieser. It was also hit with a claim that it knowingly defrauded advertisers about the amount of time users were spending watching videos on its site.

Investors should expect more to come, Wieser suggested in his note. Facebook simply hasn't put in place systems that might anticipate problems and correct them before they came to light or caused damage to the company or its users, he said.

"The underlying problem that we see is that the company has been so focused on growth at any cost that it has failed to sufficiently invest in [such] processes," he said.

Facebook's clean-up effort will come at a price

Facebook has started to try to clean up and better police its site. It's tweaked the way its News Feed works to emphasize posts from other users, rather than those from organizations. It's started to label political ads and force the backers of such ads to be identified. And it's in the process of doubling its team of content moderators to 20,000 people.

Those steps are likely going to come with significant costs for the company, Wieser said. Those costs will likely weigh down its future earnings, but still may not be the end of its misery.

"As problems are fixed, costs will rise, possibly faster than the company has anticipated (if only because the company is slow to acknowledge problems requiring fixing)," he said. "And then other problems with more material commercial consequences might still come to light."

But Facebook faces an even bigger threat than having to spend more money to clean up its messes, Wieser said. The growth in the digital advertising market is likely to slow, putting a crimp on it longer term prospects.

In his note, Wieser's reiterated his $131 price target for Facebook's stock. The company's shares closed regular trading Wednesday at $159.42, down 64 cents or 0.4%. The stock is down 10% in the year to date.

Now read: